Critical Decision Points When Selecting EGFR-Targeted Therapy for NSCLC - Episode 3

Approaches to Patient Shared Decision-Making in EGFR-Mutated NSCLC

,

Panelists discuss how medical professionals use shared decision-making by aligning treatment options with patient values, discussing benefits, risks, and preferences. Patients often prioritize longest progression-free survival (PFS), lowest toxicity, and shortest infusion time. Collaborative discussions ensure personalized, evidence-based care.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Frontline Treatment Options in Metastatic EGFR-Mutated NSCLC
    EP. 2: EGFR-Mutated NSCLC Disease Risk Stratification
    Now Viewing
    EP. 3: Approaches to Patient Shared Decision-Making in EGFR-Mutated NSCLC
    EP. 4: Maximizing Time on Therapy to Preserve Future Treatment Options in EGFR-Mutated NSCLC
    EP. 5: Expert Thoughts on Continuing Osimertinib Therapy Beyond First Disease Progression in EGFR-Mutant NSCLC
    EP. 6: Treatment Sequencing in the Second Line and Beyond in EGFR-Mutant NSCLC
    EP. 7: Amivantamab Toxicity Mitigation Strategies in the Treatment of EGFR-Mutant NSCLC
    EP. 8: Future Treatment Options in EGFR-Mutant NSCLC

    Video content above is prompted by the following:

    How do you incorporate shared decision-making when selecting the most appropriate initial treatment option for a patient and what do you find patients value most (eg, longest PFS, lowest toxicity, shortest infusion time commitment)?

    x